Primary Cardiovascular Event Prevention with Bempedoic Acid in Statin-Intolerant Indian Patients
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a primary prevention cohort (n=65) without ASCVD but with >3 cardiovascular risk factors and contraindications to statin therapy, bempedoic acid monotherapy achieved a 25.6% LDL-C reduction at 9 months.
“In a primary prevention cohort (n = 65) without ASCVD but with >3 cardiovascular risk factors and contraindications to statin therapy (baseline LDL-C = 139 mg/dL), bempedoic acid monotherapy achieved a 25.6% LDL-C reduction at 9-month follow-up [29].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [29]
Gout was reported in approximately 2% to 3% of patients (2 of 83 to 2 of 65) on bempedoic acid.
“Across studies that reported specific AEs, bempedoic acid was generally well tolerated, with myalgia reported in 6% of patients (12 of 200) [39]; gout in approximately 2% to 3% of patients (2 of 83 to 2 of 65) [28,29]; elevated liver enzymes in 1.2% to 3% of patients (1 of 85 to 6 of 200) [28,39]; cholelithiasis in 2.7% of patients (2 of 65) [29]; and new-onset diabetes in 2% of patients (4 of 200”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [29]
Real-world LDL-C reductions with bempedoic acid in primary prevention populations ranged from 23% to 39%.
“These reductions were reported across both primary (23% to 39%) [24,29,44] and secondary prevention populations (15% to 39%) [25,32,38,39].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [29]
Cholelithiasis was reported in 2.7% of patients (2 of 65) on bempedoic acid.
“Across studies that reported specific AEs, bempedoic acid was generally well tolerated, with myalgia reported in 6% of patients (12 of 200) [39]; gout in approximately 2% to 3% of patients (2 of 83 to 2 of 65) [28,29]; elevated liver enzymes in 1.2% to 3% of patients (1 of 85 to 6 of 200) [28,39]; cholelithiasis in 2.7% of patients (2 of 65) [29]; and new-onset diabetes in 2% of patients (4 of 200”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [29]
An increased incidence of gout was observed with bempedoic acid.
“An increased incidence of gout was observed with bempedoic acid [28,29]; higher discontinuation rates observed (up to 36%) [23,28,30,40] likely reflect the broader inclusion of patients with statin intolerance or LLT non-tolerance, although reasons for discontinuation were not consistently reported.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [29]
LDL-C reductions with bempedoic acid in statin-intolerant patients ranged from 22% to 38%.
“Consistent effects were also seen when bempedoic acid was added to statins (15% to 39%) [25,30,32,38,39,44], and when used in statin intolerant patients (22% to 38%) [24,29,34,35,37,40,41], despite the latter group having higher baseline LDL-C.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [29]
Cites
Still being checked.
Cited by
Sorted by citations
Systematic literature review on the real-world effectiveness and safety of bempedoic acid
Cicero, A. F. G., Cannon, C. P., Gautam, R., Anwar, S., Ghatak, A., Sarnes, E., Powell, H. A., Chhabra, R., & Jawla, S. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100562 · Cited by 1 · see citing works
“…to initiation of bempedoic acid, patients had LDL-C levels ranging from 90 mg/dL to 146 mg/dL. Diabetes was present in 11% to 66% of patients [23,25,29,30,32,38, 39,41,42]; hypertension in 33% to 83% [23,25,29,30,32,39,42,44]; and one study focusing on HIV reported HIV in 100% of patients [28].”
Influential
- Authors
- Jariwala, P., & Pramod, G.
- Affiliations
- Yashoda Hospital (IN)
- Corresponding author
- Jariwala, Pankaj
- ORCID
- Jariwala, Pankaj
- Venue
- Indian Heart Journal
- Publisher
- Elsevier BV
- Published
- 2023-12
- Volume
- 75
- Pages
- S67
- ISSN
- 0019-4832 (ISSN-L)
- OpenAlex
- W4389395350
- Cited by
- 1
- References
- 0
- Citations by year
- 2026: 1
- FWCI
- 0.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Indian Heart Journal (publishedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- bempedoic acid, primary prevention of cardiovascular disease, statin intolerance, statin adverse effects, cardiovascular risk reduction, Indian patients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
